Holen Sie sich die Stockscreener-App
1.94
1.57%
0.03
Handel nachbörslich:
1.93
-0.01
-0.52%
Schlusskurs vom Vortag:
$1.91
Offen:
$1.94
24-Stunden-Volumen:
363.04K
Relative Volume:
0.19
Marktkapitalisierung:
$61.32M
Einnahmen:
$317.00K
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-1.0265
EPS:
-1.89
Netto-Cashflow:
$-49.31M
1W Leistung:
-9.77%
1M Leistung:
-13.78%
6M Leistung:
+71.68%
1J Leistung:
-70.87%
1-Tages-Spanne:
$1.90
$2.01
1-Wochen-Bereich:
$1.87
$2.20
52-Wochen-Spanne:
$1.00
$7.68
Immuneering Corp Stock (IMRX) Company Profile
Firmenname
Immuneering Corp
Sektor
Branche
Telefon
617-500-8080
Adresse
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Vergleichen Sie IMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
1.94 | 61.32M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-15 | Bestätigt | Needham | Buy |
| 2024-03-15 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Eingeleitet | Needham | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-04-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Eingeleitet | Mizuho | Neutral |
| 2023-02-03 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-04-01 | Eingeleitet | Oppenheimer | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
Immuneering Co. (NASDAQ:IMRX) Short Interest Update - MarketBeat
Immuneering Corporation Shares Jump 55% Following Breakthrough Pancreatic Cancer Trial Results - HPBL
Immuneering Corporation Unveils Promising Data for IMM-1-104 in Pancreatic Cancer, Plans for Expansion - HPBL
Immuneering Leads The Pack Of 3 US Penny Stocks To Consider - Simply Wall St
Immuneering Corporation Stock Soars Following Promising Updates from Phase 2a Pancreatic Cancer Trials - HPBL
Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 23.1% - MarketBeat
Immuneering Reports Positive Phase 2a Data for IMM-1-104 in Pancreatic Cancer, Expands Trial Plans - HPBL
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Immuneering reports progress in pancreatic cancer trial - Investing.com
Immuneering's (IMRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer - Markets Insider
Geode Capital Management LLC Sells 12,160 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Analysts Set Immuneering Co. (NASDAQ:IMRX) PT at $12.80 - Defense World
Immuneering (NASDAQ:IMRX) Earns Buy Rating from Chardan Capital - Defense World
Immuneering’s (IMRX) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Immuneering (NASDAQ:IMRX) Given "Buy" Rating at Chardan Capital - MarketBeat
Immuneering reports promising mid-stage readout for pancreatic cancer therapy - FirstWord Pharma
Wall Street-Heavily Traded - WDRB
Immuneering announce data update from Phase 2a trial of IMM-1-104 - TipRanks
Immuneering's (IMRX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Why Is Immuneering Stock Trading Higher On Tuesday? - AOL
Immuneering touts positive pancreatic cancer data for MEK inhibitor - Endpoints News
Exciting Cancer Therapy Breakthrough! Immuneering’s New Trial Results Amaze - elblog.pl
Immuneering Corp reports promising clinical trial data - Investing.com India
Immuneering Surges Amid Promising Trial Data! What’s Driving the Surge? - Reporteros del Sur -
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms - Markets Insider
Pre-Market Boost For Immuneering (IMRX) As Trial Data Impresses Investors - Stocks Telegraph
Immuneering stock jumps on lead asset data (IMRX:NASDAQ) - Seeking Alpha
Immuneering stock soars on promising pancreatic cancer trial results By Investing.com - Investing.com South Africa
Immuneering stock soars on promising pancreatic cancer trial results - Investing.com India
Immuneering (IMRX) Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms - StreetInsider.com
Immuneering Announces Positive Data Update from Three - GlobeNewswire
Immuneering Co. (NASDAQ:IMRX) Sees Large Growth in Short Interest - MarketBeat
HighTower Advisors LLC Increases Stock Holdings in Immuneering Co. (NASDAQ:IMRX) - Defense World
Immuneering Forms Elite Advisory Board After FDA Fast Track Win for Pancreatic Cancer Drug - StockTitan
Immuneering Co. (NASDAQ:IMRX) Receives $12.80 Average Price Target from Analysts - Defense World
IMRXImmuneering Corporation Latest Stock News & Market Updates - StockTitan
Immuneering to Present Key Clinical Data for IMM-1-104 Pancreatic Cancer Treatment in 2025 Investor Event - StockTitan
Immuneering (NASDAQ:IMRX) Cut to Underweight at Morgan Stanley - Defense World
Morgan Stanley sees better opportunities, downgrades Immuneering shares to Underweight - Investing.com
Morgan Stanley upgrades PTC, cuts Immuneering, Amicus (PTCT:NASDAQ) - Seeking Alpha
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? - Yahoo Finance
Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Morgan Stanley - MarketBeat
FDA fast tracks Immuneering's melanoma treatment - Investing.com
Immuneering Corporation (IMRX) Granted FDA Fast Track Designation for IMM-1-104 - StreetInsider.com
Immuneering to Present Pipeline and Strategy at Piper Sandler Healthcare Conference - StockTitan
Immuneering shares retain Outperform rating amid Phase 2a progress for IMM-1-104 - Investing.com
Finanzdaten der Immuneering Corp-Aktie (IMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):